| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AKILI Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,540 | -2,94 % | DAX-Konzern Siemens Healthineers legt Zahlen vor | Siemens Healthineers startet solide ins neue Geschäftsjahr und bestätigt den Jahresausblick, wird aber vom schwachen Diagnostikgeschäft in China gebremst. Der DAX-Konzern Siemens Healthineers ist mit... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,320 | 0,00 % | Alignment Healthcare Reports 31% Year-Over-Year Membership Growth to 275,300 as of Jan. 1, 2026 | Guides year-end 2026 health plan membership range of 290,000 to 296,000. Announces its expectation that consensus adjusted EBITDA of approximately $145 million in 2026 will be within its full-year... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,350 | +0,20 % | Fresenius Medical Care: Ein Neuanfang nach turbulenten Zeiten? | ||
| FRESENIUS | 48,920 | -0,97 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Fresenius mit einem Kursziel von 53,60 Euro auf "Overweight" belassen. Nach einem Unternehmenskontakt verglich Analyst David... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,940 | 0,00 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BILLIONTOONE | 83,51 | +0,99 % | BillionToOne, Inc.: BillionToOne Provides Guidance for 2026 | MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen | |
| PROGYNY | 22,800 | 0,00 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| CONCENTRA GROUP | 22,940 | 0,00 % | Concentra Group Holdings Parent, Inc. - 8-K, Current Report | ||
| RXSIGHT | 7,940 | -4,80 % | RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer | ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen | |
| ANTERIS TECHNOLOGIES GLOBAL | 5,570 | 0,00 % | ANTERIS TECHNOLOGIES GLOBAL CORP.: Statement of CDIs on issue - AVR | ||
| PRIVIA HEALTH GROUP | 22,010 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 27,480 | -0,72 % | ANALYSE-FLASH: Barclays senkt Carl Zeiss Meditec auf 'Equal Weight' | LONDON (dpa-AFX Broker) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 6,935 | 0,00 % | LifeStance Health Gr Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) | ||
| CERIBELL | 20,150 | 0,00 % | Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution | SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with... ► Artikel lesen | |
| ONCOLOGY INSTITUTE | 2,600 | 0,00 % | The Oncology Institute reaffirms 2025 guidance, projects 2026 revenue |